CEO Denise Tyson

By Grace Shuman | Published by Tyson & Mendes | March 13, 2024

Empowering Women In Insurtech

In celebration of Women’s History Month, we sat down with Denise Tyson, a founder and CEO of Insurtech disruptor, Schaefer City Technologies. She shared with us more about her role, what Schaefer City is up to, and her experience as a female leader. Read on to learn more about Denise and what drives her!

Read More
Digital Insurance Reprint Options

Written by Denise M Tyson | Published by InsurTech | October 13, 2023

How AI could identify potential nuclear verdicts

Nuclear verdicts are occurring at an alarming rate in jurisdictions across the country and in most lines of business. According to a 2023 report from Marathon Strategies, the sum of corporate nuclear verdicts has nearly quadrupled in the past three years.

Read More
Nuclear verdicts: how can insurers protect themselves?

Published by InsurTech | April 13, 2023

Nuclear Verdicts®: How Can Insurers Protect Themselves?

How can insurance carriers protect themselves against the rising tide of 'Nuclear Verdicts®', and what should they do if the worst comes to pass?

Read More
Keeping verdicts from running away: Attorney Bob Tyson addresses nuclear verdicts

Written by Patricia L. Harman | Published by PropertyCasualty360 | April 12, 2023

Keeping verdicts from running away: Attorney Bob Tyson addresses nuclear verdicts®

At the recent ALM Complex Claims & Litigation Forum, Tyson addressed some of the factors behind an increase in the number of high-value jury awards.

Read More
Claims Business: CompScience, EagleView, Schaefer City and GGA

Published by Claims Journal | April 12, 2023

Claims Business: CompScience, EagleView, Schaefer City and GGA

CompScience Now an MGA for Nationwide, Swiss Re

Read More

Published by FinTech Global | April 6, 2023

Schaefer City Technologies launches product to help protect insurers from nuclear claims

InsurTech Schaefer City Technologies has launched its first software product designed to help insurance companies identify which claims have the potential to “go nuclear”.

Read More

Written by Patricia L. Harman | Published by PropertyCausalty360 | March 30, 2023

Can Software Help Insurance Pros Flag Claims With Nuclear Verdict® Potential?

Back when we last chatted with Bob Tyson, the strategic managing partner of civil litigation and insurance defense firm Tyson & Mendes, he had just wrapped up the inaugural edition of the Nuclear Verdicts® Defense Institute. That workshop for 18 defense lawyers and in-house counsel in the insurance industry drew on defense techniques outlined in Tyson’s book about fending off eight-digit jury awards.

Read More

Written by Gregory DL Morris | Published by Risk and Insurance | September 21, 2022

What Can Insurers Do to Prevent Nuclear Verdicts®? CLM Digs In

Massive awards to plaintiffs for non-monetary damages are increasing in frequency and severity. This CLM seminar aims to equip insurance professionals with the tools to prevent them.

Read More

Written by Robert F. Tyson | August 10, 2022

I Registered The Term Nuclear Verdicts® - Here’s Why

In October 2019, a Philadelphia jury delivered an $8 billion verdict against Johnson & Johnson for its improper marketing of the antipsychotic drug Risperdal as a treatment for some mental health disorders in children.

Read More

Written by Robert F. Tyson | March 22, 2021

Stop Nuclear Verdicts®: Compensate Like Plaintiff Lawyers

Here is a question for insurers: You are in the business of managing risk, but what have you and your defense counsel done differently in the last decade to manage or stop Nuclear Verdicts®?

Read More

Written by Erin Ayers, Advisen | September 21, 2020

Insurance industry can tackle the problem of Nuclear Verdicts®, attorney says

When it comes to Nuclear Verdicts®, the problem is real, but insurance professionals can take steps to better control the outcome of the claims process, according to Robert F. Tyson, Jr., partner with Tyson & Mendes.

Read More

Written by Robert F. Tyson | February, 2020

Nuclear Age - Combatting The Growing Problem Of Runaway Jury Verdicts

In October 2019, a Philadelphia jury delivered an $8 billion verdict against Johnson &Johnson for its improper marketing of the anti psychotic drug Risperdal as a treatment for some mental-health disorders in children. The enormous punitive damages award-in a case where compensatory damages were less than $1 million-was not an anomaly.

Read More

Cookies Consent

Our website uses cookies to make your browsing experience better. By using our site or clicking Accept, you agree to our use of cookies. Privacy Policy